Bank of America
INM icon

Bank of America’s InMed Pharmaceuticals INM Stock Holding History

Bank of America’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$24 – 8297
2024
Q3 		$24 Hold
5
– – ﹤0.01% 7941
2024
Q2 		$26 Hold
5
– – ﹤0.01% 7956
2024
Q1 		$36 Hold
5
– – ﹤0.01% 7467
2023
Q4 		$42 Buy
+5
New +$49 ﹤0.01% 7526
2023
Q3 		– Sell
-92
Closed -$1.7K – 7850
2023
Q2 		$1.7K Buy
92
+1
+1% +$24 ﹤0.01% 7168
2023
Q1 		$1.97K Buy
+91
New +$2.94K ﹤0.01% 7224
2022
Q4 		– Sell
-339
Closed -$45K – 8309
2022
Q3 		$45K Buy
+339
New +$62.7K ﹤0.01% 6721
2021
Q2 		– Sell
-32
Closed -$53K – 7886
2021
Q1 		$53K Buy
32
+7
+28% +$15K ﹤0.01% 6616
2020
Q4 		$42K Buy
+25
New +$40.6K ﹤0.01% 6385

Other funds holding INM

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Bank of America's INM Position: Q4 2024 in Review

Bank of America sold out of InMed Pharmaceuticals (INM) in Q4 2024, closing a stake of 5 shares — an estimated $24 sold.

Bank of America first reported a position in INM in Q4 2020 and held it in 9 quarters. The position peaked at $53K in Q1 2021. 5 funds tracked by Wall St. Rank hold INM as of Q4 2024.

  • Bank of America reported no remaining InMed Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Bank of America sold 5 InMed Pharmaceuticals shares in Q4 2024, an estimated $24.
  • Bank of America first reported a position in InMed Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • Bank of America's InMed Pharmaceuticals position peaked at $53K in Q1 2021.
  • 5 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q4 2024.

Based on Bank of America's 13F filing for Q4 2024, filed 14 Feb 2025.